RxDoctor Payments Data

Charles Godwin, MD

Psychiatry · New Bern, NCNPI 1164496592

Payments from drug & device makers

$1,661in general payments, 2019–2025

Across 48 payments — averaging $34.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$333
  • Otsuka America Pharmaceutical, Inc.$214
  • Neurocrine Biosciences, Inc.$195
  • Axsome Therapeutics, Inc.$145
  • Johnson & Johnson$132
  • AbbVie$130
  • plus $512 from 13 others

What the payments were for

  • Food & beverage$1,57795%
  • Education$845%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,661 in reported general payments places this provider in the 75th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$62,544
Medicare patients
161
Services billed
600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl31$46,200
RexultiBrexpiprazole22$45,538
BelsomraSuvorexant25$13,496
TrintellixVortioxetine Hydrobromide17$9,991
Quetiapine Fumarate ErQuetiapine Fumarate41$6,800
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine108$4,374
Clozapine39$3,958
Duloxetine Hcl173$3,432
Aripiprazole99$2,458
Zolpidem Tartrate ErZolpidem Tartrate57$2,420
Lorazepam222$2,348
Quetiapine Fumarate169$2,345
Bupropion XlBupropion Hcl100$2,280
Venlafaxine Hcl ErVenlafaxine Hcl96$2,025
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine43$1,891

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$130$46,20031 claims
Otsuka America Pharmaceutical, Inc.Rexulti$214$45,53822 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$20$9,99117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in New Bern

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →